BCAL Diagnostics Limited (BDX.AX)
ASX · AUD · Healthcare · Diagnostics & Research
A$0.08 (+0.00%) as of
Key statistics
- Market cap
- 29.49M
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0520 – 0.1550
- Beta
- 0.74
- Revenue (TTM)
- 2.35M
- Profit margin
- 0.00%
- Volume
- 46.65k
About BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Sydney, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.